SCHEMBL4157702

SCHEMBL4157702

N#Cc1cc(-c2nc3cncnc3[nH]2)ccc1Oc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 9/20 0.44
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
KMT2A Q03164 3/20 0.41
SCN9A Q15858 3/20 0.40
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2C9 P11712 1/20 0.39
KCNH2 Q12809 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
SLC22A11 Q9NSA0 1/20 0.39
CYP1A2 P05177 1/20 0.39
XDH P47989 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2535698 0.78 SLC22A12 (0.44) SLC22A12KDM4EMEN1ALDH1A1HPGD
SCHEMBL4143532 0.78 SCN9A (0.42) SLC22A12KDM4EMEN1ALDH1A1HPGD
SCHEMBL10963864 0.73 CYP11B1 (0.46) KDM4EMEN1ALDH1A1HPGDKMT2A
SCHEMBL11007176 0.73 KDM4E (0.36) KDM4EALDH1A1HPGD
SCHEMBL11236954 0.70 KDM4E (0.57) KDM4EMEN1ALDH1A1HPGDKMT2A
SCHEMBL21340368 0.70 SCN9A (0.43) SLC22A12SCN9A
SCHEMBL23207342 0.70 ALDH1A1 (0.35) KDM4EMEN1ALDH1A1HPGDKMT2A
SCHEMBL10964326 0.69 EGFR (0.51) KDM4EMEN1ALDH1A1HPGDKMT2A
SCHEMBL6283098 0.69 KDM4E (0.46) KDM4EMEN1ALDH1A1HPGDKMT2A
SCHEMBL10965164 0.69 KDM4E (0.52) KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3263109-B1 DRUG FOR PREVENTING AND/OR TREATING DEMENTIA NAT UNIV CORP TOTTORI UNIV (JP) 2020-06-17 EP claimed
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR NIPPON CHEMIPHAR CO., LTD. (JP) 2009-06-11 US disclosed
EP-1911760-A1 XANTHINE OXIDASE INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR XDH, PNPO, CBR1 SLC22A12 1556/4885KDM4E 2299/4885MEN1 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.